AngioDynamics buys Vortex for $15M

Editorial Staff | | Cardiovascular Business | Vascular & Endovascular

AngioDynamics, a developer of medical devices for vascular access, surgery, peripheral vascular disease and oncology, has completed the acquisition of Vortex Medical, a privately held, Norwell, Mass.-based developer of medical devices for venous drainage and the removal of thrombus from occluded blood vessels, for $15 million in cash.

Vortex is currently commercializing the AngioVac venous drainage system, which includes the AngioVac Cannula and Circuit. The AngioVac Cannula has a balloon-actuated, expandable, funnel-shaped distal tip that enhances flow, prevents clogging of the cannula and facilitates en bloc, or whole removal of intravascular material, according to the Albany, N.Y.-based AngioDynamics. Both the AngioVac Cannula and Circuit are FDA-cleared for use during extracorporeal bypass for up to six hours, and an application has been filed for CE Mark approval.

"We anticipate the transaction will be accretive to GAAP EPS in the first half of fiscal 2014," said Joseph M. DeVivo, president and CEO of AngioDynamics.

This acquisition is not the company's first, or largest, venture into cardiovascular-related device makers this year. In February, AngioDynamics began plans to buy Navilyst Medical from Avista Capital Partners for $372 million in cash and stock. Navilyst has products in the vascular access, interventional radiology and interventional cardiology markets.

Editorial Staff

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."